BPC-157

BPC-157 is a synthetic 15-amino-acid peptide derived from a partial fragment of body protection compound, a protein found in human gastric juice. It is one of the most-studied peptides in the animal-model tissue-repair literature.

In the US: BPC-157 is on FDA Category 2 of the 503A bulks list (Sept 2023 update), meaning compounding pharmacies cannot prepare it. It is sold as a research-grade chemical reference compound. WADA prohibits it in all sports under S0.

Animal studies report a plasma half-life around 4 hours after intraperitoneal administration. The peptide is also reported to remain stable in human gastric juice for over 24 hours, which is unusual and theorized to underpin oral activity in animals.

Animal studies show oral and drinking-water routes preserve activity, attributed to the unusual gastric-juice stability. Human oral bioavailability has not been characterized in clinical trials.

BPC-157 is a 15-aa gastric-derived peptide acting through VEGF/NO pathways and growth-hormone-receptor upregulation. TB-500 is a 7-aa Thymosin Beta-4 fragment that sequesters G-actin. Different mechanisms. They are commonly stacked in recovery research.

Limited. Sikiric et al. ran early-phase ulcerative colitis trials (PL 14736 designation). No completed Phase 3 trials registered. ClinicalTrials.gov lists exploratory studies that have not enrolled at scale.

No. BPC-157 is not FDA-approved for any human indication.

Published animal-model protocols typically span 2–8 weeks of daily administration. Community-reported research protocols cite 8–12 week cycles, though those are not clinical recommendations.

Animal toxicology shows a wide therapeutic window with no documented LD1. Human safety data are limited. Theoretical concerns include unstudied effects in active malignancy (via angiogenesis) and pregnancy.

Animal-model evidence is substantial: Achilles detachment in rats showed accelerated tendon-to-bone healing (Krivic et al. 2006 PMID 16583442). Transected quadriceps showed accelerated functional recovery (Staresinic et al. 2006 PMID 16609979). Human translation is not yet validated by RCT.

Proposed mechanisms include upregulation of growth-hormone-receptor expression in injured tissue, VEGF-driven angiogenesis, modulation of the nitric-oxide pathway in vascular endothelium, and activation of FAK-paxillin signaling. BPC-157 does not bind a single canonical receptor; its activity appears permissive of healing processes already underway.

Collagen peptides are dietary protein hydrolysates supplying amino acid building blocks. BPC-157 is a defined synthetic 15-aa sequence acting as a pharmacological signaling molecule. Completely different category and mechanism.

Stacking BPC-157 + TB-500 is the most common recovery research stack referenced in community protocols, on the theory of complementary mechanisms (BPC-157 angiogenesis + TB-500 actin-cytoskeleton-driven cell migration). No published RCT validates the combination.

Research-grade BPC-157 is synthesized via solid-phase peptide synthesis at certified peptide manufacturing facilities. Peppu Studio publishes per-batch Certificates of Analysis showing HPLC purity and identity confirmation.

Lyophilized BPC-157 is stable at 4 °C for at least 24 months and indefinitely at −20 °C. Reconstituted solution should be stored at 2–8 °C and used within 28 days. Do not freeze the reconstituted solution.

The September 2023 503A bulks-list update placed BPC-157 in Category 2, citing insufficient evidence for the FDA to determine that compounding it for routine clinical use is safe and effective. The substance remains available as a research-grade chemical reference compound.

Animal-model evidence is strong: rat ulcerative colitis, ileoileal anastomosis (Vuksic 2007), gastric-mucosal protection studies (Sikiric multi-paper). Human evidence is limited to early-phase ulcerative colitis trial work under the PL 14736 designation.

Full BPC is a larger protein found in human gastric juice. BPC-157 is a 15-amino-acid fragment of that protein (residues 134-148 of the parent sequence). The fragment retains the cytoprotective and tissue-remodeling activities of the parent.